NSE: SHILPAMED | BSE: 530549

Mid-range Performer

Download real time

850.45 4.20 (0.50%)

53.23% Gain from 52W Low

35,335 NSE+BSE Volume

NSE 01 Sep, 2025 3:31 PM (IST)

8,316.6

Market Cap

Above industry Median

1.2

Beta 1Year

Very High Volatility

Dividend

Shilpa Medicare Ltd. has an upcoming dividend of ₹1.00 per share due on 17 Sep 2025 See details

Shilpa Medicare Ltd. share price target and research reports

Name: Latest research reports of Shilpa Medicare Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Shilpa Medicare Ltd.
Rating: 5
Author: Motilal Oswal

Latest analyst research reports with target prices and PDF download for SHILPAMED, BSE:530549 Shilpa Medicare Ltd.

Shilpa Medicare Ltd.

19 Mar 2018

850.45

0.50%

Shilpa Medicare : EIR lowers regulatory risk over medium term

Buy: Shilpa Medicare Ltd.

Motilal Oswal

The receipt of establishment inspection report (EIR), with unchanged status - voluntary action initiated (VAI) - for the Jadcherla formulations facility from the USFDA is a positive. It minimizes regulatory risk over the medium term. SLPA's ANDA pipeline remains robust. We expect 16% CAGR in sales to INR12b and 35% CAGR in PAT to INR2.7b over FY17-20. Our price target of INR749 implies 53% upside. We re-iterate Buy

Shilpa Medicare Ltd. has gained 39.40% in the last 6 Months

Shilpa Medicare Ltd.

13 Feb 2018

850.45

0.50%

Shilpa Medicare : One-offs led weak results; Outlook remains promising

Buy: Shilpa Medicare Ltd.

Target

Motilal Oswal

We have reduced our EPS estimates by 26%/11%/11% for FY18E/19E/20E to factor 1) increased RM prices in CRAMS and 2) deferment of US business due to inspection related hurdle and equipment related issue. Accordingly, we have revised our price target to INR749 (from INR797 earlier) by valuing at 25x 12m forward earnings.Though Q3FY18 results were weak, we remain positive as SLPA has robust ANDA pipeline for US market, which is the key growth driver, subject to approval. Maintain Buy on potential upside of 47% from current levels

Shilpa Medicare Ltd. has gained 39.40% in the last 6 Months

Shilpa Medicare Ltd.

05 Oct 2017

850.45

0.50%

Shilpa Medicare: Strong pipeline and forward integration to drive ear

Buy: Shilpa Medicare Ltd.

Motilal Oswal

We recently met Shilpa Medicare's (SLPA) management to get an update on its business segments. The company is progressing well on ANDA filings, with cumulative pending approvals of 26. With a low base in the US market, sales there are expected to ramp-up, led by its existing products and new approvals. We expect SLPA to deliver US revenue of INR4b in FY20, significantly higher than INR250m in FY17. The company is well positioned in the Europe market too, with marketing authorization in place and likely tie-ups with marketing agencies. In addition to injectables, SLPA has started R&D; in transdermal patches. We continue to like SLPA, as the key positives are in place to drive...

Shilpa Medicare Ltd. is trading below its 30 day SMA of 873.3

Shilpa Medicare Ltd.

30 May 2015

850.45

0.50%

Shilpa Medicare Ltd: Q4FY15 Results First Cut - Flat Revenues With Improved Prof... (May 30, 2015)

Shilpa Medicare Ltd.

Karvy

The Q4FY15 revenue declined by 0.4% YoY and grew at 7.9% QoQ. The company has maintained the revenue growth achieved in FY14 (at 54% YoY) at 7.4% YoY for FY15. The company's ascent in operating margins continues as it reported an EBITDA margin of 22.7% in Q4FY15, an increase of 87 bps QoQ and 147 bps YoY

Shilpa Medicare Ltd. is trading below its 30 day SMA of 873.3

Shilpa Medicare Ltd.

20 Apr 2015

850.45

0.50%

Shilpa Medicare Ltd:Time to reap returns from the assets/opportunities built-up (Apr 20, 2015)

Hold: Shilpa Medicare Ltd.

Karvy

Shilpa Medicare (SLPA) is a pharmaceutical company with operations in oncology API manufacturing and custom synthesis. The company has invested in creating dedicated facilities for custom synthesis, foraying into formulation sales and reaching out to USA through the base business of APIs.

Shilpa Medicare Ltd. has gained 39.40% in the last 6 Months

Is Shilpa Medicare Ltd. worth buying?

247 Votes:

Buy 78.95%

Sell 11.74%

Hold 9.31%